In a reshaped strategy, OssDsign has accelerated its efforts to establish Catalyst in the US spinal fusion market, and will allocate additional capital to sales and marketing and R&D, which we argue is a natural decision given that more than 90% of the spine orthobiologics market remains untapped. The recent PROPEL data, including an 88.4% fusion rate in a highly complex patient cohort, suggests Catalyst is worth investing in.
LÄS MER
